Drug
MK 4002
MK 4002: highest development phase Phase 1, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-4002 NCT04184050 | Phase 1 | Multiple Myeloma in Relapse |
Latest
No recent events.
Follow MK 4002 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.